AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to…
24 Apr 2025
Repertoire and Genentech to develop autoimmune disease therapies
Repertoire Immune Medicines has signed a partnership and licensing agreement with Roche’s Genentech, focusing on the discovery and development of T cell-targeted immune medicines for treating an autoimmune condition. In…
24 Apr 2025
Biogen’s Friedreich’s ataxia treatment authorised in UK
Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its Skyclarys (omaveloxolone) to treat Friedreich's ataxia in individuals aged 16 years and…
23 Apr 2025
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic disorder drug tirzepatide, marking the latest power struggle between weight loss drug developers…
23 Apr 2025
Veraxa to go public in $1.6bn SPAC deal with Voyager
Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare special purpose acquisition company (SPAC). The deal, expected…
23 Apr 2025
EditCo Bio secures access to Promega’s technologies in licensing deal
EditCo Bio has entered a strategic licensing agreement with Promega, securing access to the latter’s protein-tagging and bioluminescent identification technologies. Promega's HiBiT, HaloTag, and NanoLuc technologies will be integrated into…
23 Apr 2025
Boehringer to expand oncology presence with $572m Tessellate Bio deal
Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer therapies for tumours that rely on the alternative lengthening of telomeres (ALT) mechanism…